Featured

ChemoLock

The first needlefree CSTD to receive FDA 510(k) clearance for both pharmacy compounding (ONB) and patient administration (FPA) applications.

Oncology Products

Clinical Evidence

Microbial Ingress Study for ChemoLock™ Devices (45 KB)

Report of a study commissioned by ICU and conducted by AAIPharma Services

Evaluation of ICU Medical’s ChemoLock ™ System Using Methotrexate (MTX) as a Marker (261 KB)

Conducted at RJ Lee Group, Inc., Greene County, PA

Hazardous Drug Compatibility with the ChemoClave™ System (107 KB)

Evaluation of Surface Contamination with Cyclophosphamide Following Simulated Hazardous Drug Preparation Activities Using Two Closed-System Products (66 KB)

Zock M, Soefje S, Rickabaugh K, Journal of Oncology Pharmacy Practice, Aug 10, 2010

Cost Determination Study of Closed System Transfer Devices (CSTD) (110 KB)

Barnachea L, Lee T, Gitler J, Saria M. Presented at the California Society of Health System Pharmacists (CSHP), November 4, 2011

Economic and Environmental Impact of Commercially Available Closed System Transfer Devices (CSTDs) (114 KB)

How the ICU Medical ChemoClave™ — the world’s only needlefree CSTD — can provide nearly $482K in annual cost savings while generating more than 3,200 fewer pounds of biohazardous waste per year

Creating a Culture of Closure: Implementation of the ICU Medical Chemotherapy Closed System for Antineoplastic Agent Administration (146 KB)

Moore A, Wiley K, Maloney K, Holmes M, Hospital of the University of Pennsylvania. Presented at the Oncology Nursing Society Meeting, May 2012

Performance Evaluation of the PhaSeal® Luer Lock Injector (N35) and Connector™ Luer Lock (C45 & C40) in a Lab Study (96 KB)

Dirty Little Secrets: Hazardous Drug Contamination at the Chairside (138 KB)

Hodges L., Caskey C. Section on Hematology and Oncology/Environmental Health and Safety Department, Wake Forest University School of Medicine

Spiros: Mechanically and Microbiologically Closed Male Luer (82 KB)

Improving Chemotherapy Safety via Use of ChemoClave® System (Spiros®), Priming Technique, DoseEdge™, and Volutrols (123 KB)

Michelle Abitz, RN; Caitlyn Burdock, RN, BSN; Micha Koentz, BS, PharmD; Rhiannon McDonnell, RN, BSN; Heidi Trinkman, BS, PharmD

Reducing Hazardous Drug Exposure: Are All Closed Systems Created Equal? (290 KB)

Karen Sachse, MSN, RN, CPON, CNS-BC, Margaret Perry, BSN, RN, CPHON, CPN, and Radha Rohatgi, Pharm D, BCOP, Hematology and Oncology, Children’s National Medical Center, Washington, DC